SAMSUNG-DISPLAY
12.8.2020 10:21:10 CEST | Business Wire | Press release
Samsung Display Company today revealed new display technology that features a remarkable power-saving function for mobile electronics, being commercialized for the first time in Galaxy Note 20 Ultra 5G flagship smartphones.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200812005278/en/
The display company has now successfully commercialized its low-power OLED adaptive frequency technology, which can curtail the operating power of a phone’s display by as much as 22 percent over existing smartphones now in general use.
“High-definition video streaming and gaming are expanding their capabilities in line with 5G commercialization, creating a widespread need for display panel technologies that can enable greater power savings,” said Ho-Jung Lee, Vice President of the mobile display product planning team for Samsung Display.
“Our Adaptive Frequency display technology is expected to considerably enhance the user experience by calibrating refresh rates in line with the requirements of a specific application and therein more precisely allocating available power. This will free up time for other smartphone operations,” Lee added.
The company’s power-saving technology allows the display panel to utilize variable refresh rates that consume the least possible amount of power for each type of application. The adaptive frequency technology supports a 120Hz scan rate for playing mobile games that require speedy frame changes, a 60Hz rate for movie streaming, a 30Hz rate for email correspondence, and a 10Hz rate for viewing still images or browsing social networking services.
Existing smartphone panels offer only a fixed refresh rate. They cannot automatically calibrate a phone’s refresh rate, which would result in image flickering caused by luminance differences at lower refresh rates. Samsung Display’s new backplane** technology eliminates flickering for operating frequencies as low as 10Hz.
In particular, when displaying still images, the new variable-rate panel has proven to save 60 percent of operating power by introducing a low-frequency refresh rate of 10Hz, while conventional panels unnecessarily waste power through the use of a consistent, fixed frequency regardless of the type of content.
The world-leading display company also anticipates employing this cutting-edge, power-saving technology with other advanced IT products in the future, to help boost material efficiency and optimize the functionality of operating components.
About Samsung Display
Samsung Display Co., Ltd. is a global leader in display panel market, with OLED and LCD technologies and products. Samsung Display has seven production facilities and five branch sales offices worldwide. The company specializes in high-quality displays for consumer, mobile, IT and industrial usage, including those featuring OLED (organic light emitting diode) and LCD technologies. As a total solution provider, Samsung Display strives to advance the future with next-generation technologies featuring ultra-thin, energy-efficient, flexible, and transparent displays. For more information, please visit www.samsungdisplay.com .
* Refresh or Scan Rate:
The number of frames that a display panel delivers in one second. For example, a 120Hz refresh rate accounts for 120 frame changes. Higher scan rates result in more lively and natural-appearing images.
** Backplane Technology
Making substrates such as glass and polyimide (PI) that are comprised of thin-film transistors (TFTs) required to operate pixels, the minimum unit comprising most display panels.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200812005278/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom